Another DOAC Fails in the Setting of Mechanical Heart Valves

The PROACT Xa trial of apixaban has been stopped due to an excess risk of blood clots compared with warfarin.

Related Keywords

New York , United States , Canada , Iqbal Jaffer , Isaac George , Twitter , Boehringer Ingelheim , Phd Mcmaster University , Bristol Myers Squibb , Presbyterian Columbia University Irving Medical Center , Columbia University Irving Medical Center , Mcmaster University ,